Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mesalamine
Drug ID BADD_D01397
Description An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022]. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent [A174019]. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules [A174019]. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Indications and Usage For the treatment of active ulcerative proctitis.
Marketing Status Prescription; Discontinued
ATC Code A07EC02
DrugBank ID DB00244
KEGG ID D00377
MeSH ID D019804
PubChem ID 4075
TTD Drug ID D0C4YC
NDC Product Code 12598-5158; 68743-476; 59651-396; 12598-9554; 0023-5853; 45802-923; 68682-113; 12598-9154; 68382-452; 60687-397; 12598-9157; 0023-5901; 31722-005; 12598-5157; 0023-5801; 70771-1353; 54092-189; 62991-2705; 54127-0947; 0378-9230; 50090-4168; 49957-511; 42291-563; 49706-0882; 70748-214; 63552-042; 58914-501; 70600-006; 69238-1274; 63629-8678; 62559-420; 62756-115; 49706-8821; 12598-9155; 70710-1543; 54092-191; 54092-476; 16714-245; 16714-830; 63629-2397; 0093-5907; 42291-564; 67877-717; 57297-192; 49964-0015; 47621-059; 0093-9224; 63552-043; 63304-175; 59762-0118; 60687-556; 70771-1110; 51407-274; 54127-0945; 0781-7088; 70771-1071; 50090-3497; 0037-0022; 54127-0950; 45802-929; 70771-1513; 62512-0072; 42419-024; 0472-1915; 49452-0450; 0023-5854; 0378-1375; 43353-884; 70710-1302; 54092-100; 12651-582; 59285-037; 54127-0943; 62350-0076; 69918-560; 0591-2245; 24528-0003; 60687-408; 63629-8679; 12598-9553; 0904-6832; 62331-060; 12598-5163; 64980-282; 70771-1625; 68382-435; 57451-1141; 11014-0129; 67454-001; 51927-1078; 0037-0066; 70518-3239; 63629-8827; 59762-0117; 12598-9151; 45802-098; 68382-711; 65649-103; 50090-3002
Synonyms Mesalamine | Mesalazine | m-Aminosalicylic Acid | m Aminosalicylic Acid | 5-Aminosalicylic Acid | 5 Aminosalicylic Acid | meta-Aminosalicylic Acid | meta Aminosalicylic Acid | Asacol | Asacolon | Ascolitin | Canasa | Claversal | Fivasa | Salofalk | Lixacol | Mesalamine Hydrochloride | Hydrochloride, Mesalamine | Mesalamine Monosodium Salt | Monosodium Salt, Mesalamine | Mesasal | Novo-5 ASA | Novo 5 ASA | Pentasa | Rowasa | 5-Aminosalicylate | 5 Aminosalicylate
Chemical Information
Molecular Formula C7H7NO3
CAS Registry Number 89-57-6
SMILES C1=CC(=C(C=C1N)C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coma17.02.09.001--Not Available
Condition aggravated08.01.03.004--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
Creatinine renal clearance decreased13.13.01.013--Not Available
Crohn's disease07.08.01.015; 10.02.01.005--Not Available
Cystitis11.01.14.001; 20.03.02.002--
Deafness04.02.01.001--Not Available
Defaecation urgency07.02.04.001--Not Available
Delirium19.13.02.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.002--
Dermatitis infected23.03.04.024; 11.01.12.011--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.002--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug ineffective08.06.01.006--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Duodenal ulcer07.04.02.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dysmenorrhoea21.01.01.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages